Conversations to Improve Opioid Treatment Initiation
Aim 2 - Conversations Can Save Lives: TALKing About Buprenorphine & Methadone for Opioid Use Treatment Initiation (TALK ABOUT It)
This study is testing a new conversation tool to help emergency department patients with opioid use disorder start treatment with medications like buprenorphine and methadone.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 75 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Baystate Medical Center Academic / other |
| Locations | 1 site (Springfield, Massachusetts) |
| Trial ID | NCT06527820 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance the initiation of medications for opioid use disorder (OUD) in emergency department patients by implementing a conversation aid called 'Talk About It.' The intervention focuses on fostering shared decision-making between patients and clinicians regarding the use of buprenorphine and methadone, which are effective treatments for OUD. Participants will be enrolled and followed before and after the intervention to assess its impact on medication initiation, adherence, and patient-reported outcomes. The goal is to meet patients where they are and improve access to life-saving treatment options.
Who should consider this trial
Good fit: Ideal candidates for this study are patients aged 16 and older who present with indications for medication initiation for opioid use disorder and are not currently on buprenorphine or methadone.
Not a fit: Patients who do not have opioid use disorder or are already receiving medication for opioid use disorder will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly increase the number of patients receiving effective treatment for opioid use disorder in emergency settings.
How similar studies have performed: Other studies have shown success with similar patient-centered approaches to addiction treatment, indicating potential for this intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 16 and older * presenting with indications for Medications for Opioid Use Disorder (MOUD) initiation (opioid overdose, opioid withdrawal, complications of injection opioid use, untreated OUD) * not currently on buprenorphine or methadone (in the past 7 days). (Buprenorphine is FDA approved for patients aged 16 and older, so 16- and 17-year-olds may be included with parental consent.) Exclusion Criteria: * No Opioid Use Disorder (OUD) * already on MOUD
Where this trial is running
Springfield, Massachusetts
- Baystate Medical Center — Springfield, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Elizabeth Schoenfeld, MD, MS
- Email: elizschoen@gmail.com
- Phone: 4137940000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.